 Connection
Elizabeth Bayliss to Drug-Related Side Effects and Adverse Reactions
This is a "connection" page, showing publications Elizabeth Bayliss has written about Drug-Related Side Effects and Adverse Reactions.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.592 |
|
|
|
-
Boyd CM, Shetterly SM, Powers JD, Weffald LA, Green AR, Sheehan OC, Reeve E, Drace ML, Norton JD, Maiyani M, Gleason KS, Sawyer JK, Maciejewski ML, Wolff JL, Kraus C, Bayliss EA. Evaluating the Safety of an Educational Deprescribing Intervention: Lessons from the Optimize Trial. Drugs Aging. 2024 Jan; 41(1):45-54.
Score: 0.745
-
Bayliss EA, Albers K, Gleason K, Pieper LE, Boyd CM, Campbell NL, Ensrud KE, Gray SL, Linsky AM, Mangin D, Min L, Rich MW, Steinman MA, Turner J, Vasilevskis EE, Dublin S. Recommendations for outcome measurement for deprescribing intervention studies. J Am Geriatr Soc. 2022 09; 70(9):2487-2497.
Score: 0.673
-
Sheehan OC, Gleason KS, Bayliss EA, Green AR, Drace ML, Norton J, Reeve E, Shetterly SM, Weffald LA, Sawyer JK, Maciejewski ML, Kraus C, Maiyani M, Wolff J, Boyd CM. Intervention design in cognitively impaired populations-Lessons learned from the OPTIMIZE deprescribing pragmatic trial. J Am Geriatr Soc. 2023 03; 71(3):774-784.
Score: 0.175
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|